AI Stock Analysis - Atossa Therapeutics (ATOS)
Analysis generated August 21, 2025.
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics and delivery methods for breast cancer and other breast conditions. It leverages its expertise in pharmacological advancements to create innovative solutions aimed at improving patient outcomes. The company's key emphasis is on reducing the risk of recurrence and enhancing survival rates through targeted therapies and personalized medical solutions.
Stock Alerts - Atossa Therapeutics (ATOS)
 |
Atossa Therapeutics | March 5 Price is down by -6.5% in the last 24h. |
|
Atossa Therapeutics | March 4 Price is up by 6.1% in the last 24h. |
|
Atossa Therapeutics | March 3 Price is up by 6.7% in the last 24h. |
|
Atossa Therapeutics | February 26 Price is up by 6.6% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Atossa Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 85 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 43 | Sign up | Sign up | Sign up |
| Facebook Followers | 67,319 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 94 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 63,969 | Sign up | Sign up | Sign up |
| X Followers | 3,608 | Sign up | Sign up | Sign up |
| X Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 31 | Sign up | Sign up | Sign up |
About Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
| Price | $4.78 |
| Target Price | Sign up |
| Volume | 129,981 |
| Market Cap | $39M |
| Year Range | $3.94 - $17.7 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Atossa Therapeutics Files Prospectus For Offering $50M Common SharesFebruary 20 - Benzinga |
|
 |
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 OutlookFebruary 10 - Yahoo |
Atossa Therapeutics Intends To Complete Enrollment In Combination Therapy Arms Of I-SPY 2 EOP In H2, EVANGELINE Trial By Mid-YearFebruary 10 - Benzinga |
|
|
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth CarefullyFebruary 8 - Yahoo |
 |
Atossa Therapeutics receives "Study May Proceed" letter for breast cancer studyJanuary 6 - Thefly.com |
 |
12 Health Care Stocks Moving In Wednesday's After-Market SessionFebruary 11 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 4,000 | -4,000 | -8.7M | -8.7M | -0.070 |
| Q2 '25 | 0 | 4,000 | -4,000 | -8.4M | -9M | -0.070 |
| Q1 '25 | 0 | 4,000 | -4,000 | -6.7M | -7.4M | -0.050 |
| Q4 '24 | 0 | 4,000 | -4,000 | -6.3M | -7.1M | -0.050 |
| Q3 '24 | 0 | 4,000 | -4,000 | -7.2M | -6.4M | -0.058 |
Insider Transactions View All
| QUAY STEVEN C filed to buy 13,898 shares at $0.9. May 22 '25 |
| Remmel H. Lawrence filed to buy 10,257 shares at $0.7. March 28 '25 |
| Finn Jonathan filed to buy 25,000 shares at $1.8. April 11 '24 |
| WEAVER GREGORY L filed to sell 55 shares at $0.7. November 17 '23 |
Similar companies
Read more about Atossa Therapeutics (ATOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Atossa Therapeutics
The Market Cap of Atossa Therapeutics is $39M.
Currently, the price of one share of Atossa Therapeutics stock is $4.78.
The ATOS stock price chart above provides a comprehensive visual representation of Atossa Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Atossa Therapeutics shares. Our platform offers an up-to-date ATOS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Atossa Therapeutics (ATOS) does not offer dividends to its shareholders. Investors interested in Atossa Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Atossa Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
